BR112014011219A2 - derivados de aminopirimidina como moduladores de lrrk2 - Google Patents
derivados de aminopirimidina como moduladores de lrrk2Info
- Publication number
- BR112014011219A2 BR112014011219A2 BR112014011219A BR112014011219A BR112014011219A2 BR 112014011219 A2 BR112014011219 A2 BR 112014011219A2 BR 112014011219 A BR112014011219 A BR 112014011219A BR 112014011219 A BR112014011219 A BR 112014011219A BR 112014011219 A2 BR112014011219 A2 BR 112014011219A2
- Authority
- BR
- Brazil
- Prior art keywords
- lrrk2
- aminopyrimidine derivatives
- compounds
- modulators
- lrrk2 modulators
- Prior art date
Links
- 150000005005 aminopyrimidines Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
resumo patente de invenção: "derivados de aminopirimidina como moduladores de lrrk2". a presente invenção refere-se a compostos de fórmula i: i ou sais farmaceuticamente aceitáveis do mesmo,onde a, x, r1, r2, r3 e r4 têm as definições dadas neste relatório. também estão divulgados métodos para fazer os compostos e usar os compostos para o tratamento de doenças associadas com o receptor de lrrk2, tal como mal de parkinson.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161564759P | 2011-11-29 | 2011-11-29 | |
US61/564,759 | 2011-11-29 | ||
PCT/EP2012/073788 WO2013079505A1 (en) | 2011-11-29 | 2012-11-28 | Aminopyrimidine derivatives as lrrk2 modulators |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112014011219A2 true BR112014011219A2 (pt) | 2017-04-25 |
BR112014011219A8 BR112014011219A8 (pt) | 2017-07-11 |
BR112014011219B1 BR112014011219B1 (pt) | 2022-08-23 |
Family
ID=47226189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014011219-3A BR112014011219B1 (pt) | 2011-11-29 | 2012-11-28 | Derivados de aminopirimidina, seus usos, e composição farmacêutica |
Country Status (11)
Country | Link |
---|---|
US (1) | US8796296B2 (pt) |
EP (2) | EP3121173A1 (pt) |
JP (1) | JP6185925B2 (pt) |
KR (1) | KR102012057B1 (pt) |
CN (2) | CN106349234A (pt) |
BR (1) | BR112014011219B1 (pt) |
CA (1) | CA2850594C (pt) |
ES (1) | ES2628438T3 (pt) |
MX (1) | MX348606B (pt) |
RU (1) | RU2651544C2 (pt) |
WO (1) | WO2013079505A1 (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105837519A (zh) * | 2010-06-04 | 2016-08-10 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂的氨基嘧啶衍生物 |
RS56583B1 (sr) * | 2010-11-10 | 2018-02-28 | Genentech Inc | Derivati pirazol aminopirimidina kao lrrk2 modulatori |
BR112014009717B1 (pt) * | 2011-11-29 | 2022-06-14 | Genentech, Inc | Derivados de 2-(fenil ou pirid-3-il)aminopirimidina, seus usos, e composição farmacêutica |
AR089182A1 (es) * | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
CA2871375C (en) * | 2012-05-03 | 2020-10-27 | F. Hoffmann-La Roche Ag | Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease |
WO2014134772A1 (en) * | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
WO2015176010A1 (en) | 2014-05-15 | 2015-11-19 | The United States Of America, As Represented By The Secretary, Departmentof Health & Human Services | Treatment or prevention of an intestinal disease or disorder |
WO2016007540A2 (en) | 2014-07-10 | 2016-01-14 | The J. David Gladstone Institutes | Compositions and methods for treating dengue virus infection |
CN105693524A (zh) * | 2014-11-28 | 2016-06-22 | 浙江省化工研究院有限公司 | 一种硝基化合物的制备方法 |
CN107801397B (zh) * | 2015-02-13 | 2021-07-30 | 达纳-法伯癌症研究所公司 | Lrrk2抑制剂及其制备和使用方法 |
WO2017087905A1 (en) | 2015-11-20 | 2017-05-26 | Denali Therapeutics Inc. | Compound, compositions, and methods |
US11028080B2 (en) | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
WO2017162661A1 (en) | 2016-03-22 | 2017-09-28 | Bayer Pharma Aktiengesellschaft | 1h-benzo[de]isoquinoline-1,3(2h)-diones |
HUE056678T2 (hu) | 2016-06-16 | 2022-02-28 | Denali Therapeutics Inc | Pirimidin-2-ilamino-1H-pirazolok mint LRRK2 inhibitorok neurodegeneratív rendellenességek kezelésére való alkalmazásra |
JP2020524691A (ja) | 2017-06-21 | 2020-08-20 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | IRAK4調節因子としてのピラゾロ[1,5a]ピリミジン誘導体 |
WO2018234342A1 (en) | 2017-06-21 | 2018-12-27 | F. Hoffmann-La Roche Ag | ISOINDOLINONE DERIVATIVES AS MODULATORS OF IRAK4 |
MA51222A (fr) | 2017-11-21 | 2020-10-07 | Denali Therapeutics Inc | Polymorphes et formes solides d'un composé de pyrimidinylamino-pyrazole, et procédés de production |
CA3086182A1 (en) | 2017-12-20 | 2019-06-27 | Denali Therapeutics Inc. | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds |
CN111732548B (zh) * | 2020-06-11 | 2022-06-17 | 浙江大学 | N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途 |
CN116685325A (zh) | 2020-10-20 | 2023-09-01 | 豪夫迈·罗氏有限公司 | Pd-1轴结合拮抗剂和lrrk2抑制剂的组合疗法 |
MX2023005906A (es) * | 2020-11-20 | 2023-05-26 | Denali Therapeutics Inc | Compuestos, composiciones y metodos. |
WO2024097394A1 (en) | 2022-11-03 | 2024-05-10 | Denali Therapeutics Inc. | Solid and co-crystal forms of a pyrimidine triazole compound |
WO2024112746A1 (en) | 2022-11-22 | 2024-05-30 | Denali Therapeutics Inc. | Processes and intermediates for the preparation of a pyrimidine aminopyrazole compound |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2338545T3 (es) * | 2002-12-20 | 2010-05-10 | Pfizer Products Inc. | Derivados de pirimidina para el tratamiento del crecimiento celular anormal. |
UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
RU2356901C2 (ru) * | 2003-07-30 | 2009-05-27 | Райджел Фармасьютикалз, Инк. | Соединения 2, 4-пиримидиндиамина, обладающие воздействием при аутоиммунных расстройствах |
EP1758887A1 (en) * | 2004-05-14 | 2007-03-07 | Pfizer Products Incorporated | Pyrimidine derivatives for the treatment of abnormal cell growth |
US20080131937A1 (en) | 2006-06-22 | 2008-06-05 | Applera Corporation | Conversion of Target Specific Amplification to Universal Sequencing |
WO2008051547A1 (en) * | 2006-10-23 | 2008-05-02 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
DE102007010801A1 (de) * | 2007-03-02 | 2008-09-04 | Bayer Cropscience Ag | Diaminopyrimidine als Fungizide |
CL2009000600A1 (es) * | 2008-03-20 | 2010-05-07 | Bayer Cropscience Ag | Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas. |
WO2009127642A2 (en) * | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
KR20110020940A (ko) * | 2008-06-25 | 2011-03-03 | 아이알엠 엘엘씨 | 키나제 억제제로서의 피리미딘 유도체 |
EP2440559B1 (en) * | 2009-05-05 | 2018-01-10 | Dana-Farber Cancer Institute, Inc. | Egfr inhibitors and methods of treating disorders |
ES2512727T3 (es) | 2009-09-29 | 2014-10-24 | Glaxo Group Limited | Nuevos compuestos |
CN105837519A (zh) * | 2010-06-04 | 2016-08-10 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂的氨基嘧啶衍生物 |
RS56583B1 (sr) * | 2010-11-10 | 2018-02-28 | Genentech Inc | Derivati pirazol aminopirimidina kao lrrk2 modulatori |
US9145402B2 (en) * | 2011-11-29 | 2015-09-29 | Genentech, Inc. | Aminopyrimidine derivatives as LRRK2 modulators |
AR089182A1 (es) * | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
BR112014009717B1 (pt) * | 2011-11-29 | 2022-06-14 | Genentech, Inc | Derivados de 2-(fenil ou pirid-3-il)aminopirimidina, seus usos, e composição farmacêutica |
-
2012
- 2012-11-28 CA CA2850594A patent/CA2850594C/en active Active
- 2012-11-28 CN CN201610618071.7A patent/CN106349234A/zh active Pending
- 2012-11-28 KR KR1020147017590A patent/KR102012057B1/ko active IP Right Grant
- 2012-11-28 RU RU2014124640A patent/RU2651544C2/ru active
- 2012-11-28 CN CN201280058449.2A patent/CN103958498B/zh active Active
- 2012-11-28 EP EP16180049.5A patent/EP3121173A1/en not_active Withdrawn
- 2012-11-28 BR BR112014011219-3A patent/BR112014011219B1/pt active IP Right Grant
- 2012-11-28 EP EP12791198.0A patent/EP2785709B1/en active Active
- 2012-11-28 ES ES12791198.0T patent/ES2628438T3/es active Active
- 2012-11-28 MX MX2014006204A patent/MX348606B/es active IP Right Grant
- 2012-11-28 US US13/687,429 patent/US8796296B2/en active Active
- 2012-11-28 JP JP2014543871A patent/JP6185925B2/ja active Active
- 2012-11-28 WO PCT/EP2012/073788 patent/WO2013079505A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
KR102012057B1 (ko) | 2019-08-19 |
JP2014533738A (ja) | 2014-12-15 |
CA2850594A1 (en) | 2013-06-06 |
JP6185925B2 (ja) | 2017-08-23 |
ES2628438T3 (es) | 2017-08-02 |
MX348606B (es) | 2017-06-21 |
EP2785709A1 (en) | 2014-10-08 |
US8796296B2 (en) | 2014-08-05 |
BR112014011219A8 (pt) | 2017-07-11 |
RU2651544C2 (ru) | 2018-04-20 |
CA2850594C (en) | 2020-03-10 |
RU2014124640A (ru) | 2016-01-27 |
US20130158006A1 (en) | 2013-06-20 |
BR112014011219B1 (pt) | 2022-08-23 |
CN103958498B (zh) | 2016-09-07 |
CN103958498A (zh) | 2014-07-30 |
EP3121173A1 (en) | 2017-01-25 |
MX2014006204A (es) | 2014-07-10 |
KR20140103996A (ko) | 2014-08-27 |
CN106349234A (zh) | 2017-01-25 |
EP2785709B1 (en) | 2017-05-10 |
WO2013079505A1 (en) | 2013-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014011219A2 (pt) | derivados de aminopirimidina como moduladores de lrrk2 | |
BR112014009717A8 (pt) | derivados de 2-(fenil ou pirid-3-il)aminopirimidina como moduladores de cinase lrrk2 para o tratamento de doença de parkinson. | |
BR112012030820A8 (pt) | Derivados de aminopirimidina como moduladores de lrrk2, seu uso e composição que os compreende | |
BR112014011850A2 (pt) | derivados de aminopirimidina como moduladores de lrrk2 | |
BR112014012217A2 (pt) | derivados de 2-fenilaminopirimidina como moduladores de cinase lrrk2 para o tratamento de doença de parkinson | |
BR112013011600A8 (pt) | Derivados de pirazol aminopirimidina como moduladores de lrrk2 | |
CY1118969T1 (el) | Ενωσεις πυριμιδινο-2-αμινης και η χρηση τους ως αναστολεις των κινασων jak | |
BR112014027117A2 (pt) | derivados de pirazol aminopirimidina como moduladores de lrrk2 para uso no tratamento de doença de parkinson | |
BR112014026952A2 (pt) | derivados de aminopirimidina pirazol como moduladores lrrk2 | |
ECSP10010582A (es) | Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer | |
UY32574A (es) | Antagonistas del receptor cxcr3 | |
MX2013001614A (es) | Compuestos heterociclico. | |
BR112014005468A2 (pt) | derivados de aminopiridina para uso como moduladores de atividade quinase | |
BR112013026807A2 (pt) | derivados de metil amina bicíclicos substituídos como moduladores dos receptores de esfinfgosina-1 fosfato | |
AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
MA32723B1 (fr) | Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments | |
MD20150051A2 (ro) | Derivaţi de imidazopiridazine ca modulatori ai receptorului pentru GABAA | |
BR112014012459A2 (pt) | 2h-indazóis como antagonistas do receptor de ep2 | |
BR112013029820A2 (pt) | derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona e seu uso como inibidores de quinase do receptor de vegf | |
UY32747A (es) | 2-carboxamida-cicloamino-ureas sustituidas | |
ECSP11011053A (es) | [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos | |
BR112015004292A2 (pt) | compostos do tipo indol-amida como inibidores de beta-amiloide | |
BR112013027982A2 (pt) | derivados de isoindolinona | |
TN2013000034A1 (en) | Heterocyclic compound and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: GENENTECH, INC. (US) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07B | Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 7.5 NA RPI NO 2560 DE 28/01/2020 POR TER SIDO INDEVIDA. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/11/2012, OBSERVADAS AS CONDICOES LEGAIS |